Semaglutide, sold under the brand names '''Ozempic''', '''Wegovy''' and '''Rybelsus''', is a drug used to treat [[type 2 diabetes]] and reduce obesity.  It was developed by [[Novo Nordisk]] in 2012. < ref > {{Cite journal|date=27 Oct 2021|title=Wegovy (semaglutide): a new weight loss drug for chronic weight management|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/|journal=Journal of Investigative Medicine}} < /ref >   It was approved for use in America in 2017. < ref > {{Cite web|title=Ozempic (semaglutide) FDA Approval History|url=https://www.drugs.com/history/ozempic.html|access-date=2023-03-08|website=Drugs.com|language=en}} < /ref >   It was approved in Europe in 2022  < ref > {{Cite web|last=EMA|date=2021-11-11|title=Wegovy|url=https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy|access-date=2023-03-08|website=European Medicines Agency|language=en}} < /ref >  and in the [[National Health Service]] in 2023.  
 
 People who had the weekly injection saw their weight drop by 12% on average after 68 weeks. < ref > {{Cite web|last=PA|last2=Britton|first2=Paul|date=2023-03-08|title=Weight loss injection popular with celebrities is approved for NHS use|url=https://www.manchestereveningnews.co.uk/news/greater-manchester-news/game-changer-weight-loss-injection-26415191|access-date=2023-03-08|website=Manchester Evening News|language=en}} < /ref >   It is also [[Prescription|prescribed]] for heart conditions. < ref > {{Cite news|last=Kuchler|first=Hannah|date=2023-09-01|title=Novo Nordisk briefly eclipses LVMH as Europe’s most valuable company|work=Financial Times|url=https://www.ft.com/content/97e89e94-38cb-4a22-9a17-c110e39958bc?|access-date=2023-09-02}} < /ref > 
 
 In a trial of more than 17,600 people aged above 45 with obesity who had [[cardiovascular disease]], but not diabetes, published in 2023, it  cut the risk of heart attacks by 28%. < ref > {{Cite news|last=Kuchler|first=Hannah|date=2023-11-11|title=Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows|work=Financial Times|url=https://www.ft.com/content/a204a830-4c54-4832-94d8-62b040e6fd48|access-date=2023-11-12}} < /ref > 
 
 A [[black market]] developed  in the United Kingdom in 2023 with  unlicensed semaglutide being sold through social media and in [[beauty salon]] < nowiki/ > s. < ref > {{Cite news|date=2023-11-15|title=The online black market cashing in on weight loss injection hype|language=en-GB|work=BBC News|url=https://www.bbc.com/news/health-67414203|access-date=2023-11-15}} < /ref > 
 
 ==References== 
 {{reflist}} 
 {{Oral hypoglycemics and insulin analogs}} 
 
 [[Category:Anti-diabetic drugs]] 
 [[Category:Obesity]]